Form 4 for GLUE Monte Rosa Therapeutics, Inc.
Accepted 2025-01-06 00:00:00 ET · period of report 2025-01-02 · accession 0000950170-25-002100 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-01-06 | 2025-01-02 | GLUE | Warmuth Markus | Pres, CEO, Dir | A - Grant | — | +128.0K | 544.5K | +31% | — |
| D | 2025-01-06 | 2025-01-02 | GLUE | Warmuth Markus | Pres, CEO, Dir | A - Grant | $0.00 | +575.0K | 575.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-02 | A | A | 128,000 | — | 544,538 | D | — | — | (F1) Represents restricted stock units ("RSUs") granted under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 25% of the RSUs shall vest on January 1, 2026, with the remainder vesting in 3 equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-01-02 | A | A | 575,000 | $0.00 | 575,000 | D | $7.11 · — to 2035-01-01 | 575,000 Common Stock | (F2) 25% of this option shall vest and become exercisable on January 1, 2026, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |